Group 1 - The pharmaceutical sector, particularly the innovative drug segment, has shown strong performance this year, driven by technological innovation and asset revaluation in China [1] - The traditional Chinese medicine (TCM) sector has also performed well but lags behind the innovative drug segment, making it a potential area for investment as market participants seek to "catch up" [1] - Tongrentang Technology, a leading company in the TCM industry, has demonstrated policy certainty, consumer demand, and technological empowerment potential, making it a valuable investment opportunity [1] Group 2 - In the first half of 2025, Tongrentang Technology achieved revenue of 3.74 billion RMB and a net profit of 480 million RMB, showcasing a solid operational performance [2] - The company focuses on optimizing production processes and enhancing quality management to ensure stable product supply and sustainable development [2] - Tongrentang Technology is implementing differentiated marketing strategies for its six major product lines, enhancing market penetration and customer loyalty [2] Group 3 - The company benefits from a unique combination of traditional branding, modern technology, and policy support, which enhances its market recognition and valuation potential [3] - Tongrentang Technology's long history and strong brand presence in the TCM sector provide a stable revenue and profit outlook, making it attractive in the current bull market [4] - The company is investing in smart production and research innovation, significantly improving production efficiency and supporting valuation growth [5] Group 4 - The focus on innovative drug development, particularly in cardiovascular and health supplement areas, is expected to drive future revenue growth for Tongrentang Technology [6] - National policies supporting the TCM industry present significant growth opportunities for the company, especially in international markets [7] - The TCM industry is transitioning from traditional practices to technology-driven approaches, positioning it for high-quality development [8]

Core Viewpoint - Tongrentang Technology (01666.HK) reported a sales revenue of RMB 373,850.3 million and a net profit of RMB 48,403.0 million for the six months ending June 30, 2025, indicating a focus on quality improvement and efficiency enhancement in its operations [1] Group 1: Financial Performance - The gross profit margin for the reporting period was 38.16%, an increase from 37.95% in the same period last year [1] - The company had four products with sales exceeding RMB 100 million, twenty-eight products with sales between RMB 10 million and RMB 100 million, and ten products with sales between RMB 5 million and RMB 10 million [1] - The sales revenue of the Six Flavor Rehmannia Pills series grew approximately 47.99% year-on-year, while the Jin Kui Shen Qi series and Jing Zhi Niu Huang Jie Du Pian series saw increases of 19.55% and 4.03%, respectively [1] Group 2: Strategic Initiatives - The company plans to continue implementing its "quality improvement and efficiency enhancement" strategy, focusing on reform and innovation as core themes [1] - The marketing strategy for the second half of the year will emphasize "changing concepts, promoting coordination, improving quality and efficiency, strengthening execution, enhancing management, and building confidence" [2] - The company aims to strengthen the "all-staff marketing" awareness and strictly control market order while driving innovation to expand market reach and achieve revenue and profit goals [2]

Core Viewpoint - Tong Ren Tang (600085) Technology reported a decline in revenue and net profit for the six months ending June 30, 2025, primarily due to ongoing marketing reforms aimed at improving inventory turnover and market order [1] Financial Performance - The company achieved revenue of RMB 3.739 billion, a year-on-year decrease of 7.69% [1] - Net profit attributable to shareholders was RMB 339 million, down 21.01% year-on-year [1] - Basic earnings per share were RMB 0.26 [1] Product Sales Performance - The group had four products with sales exceeding RMB 100 million [1] - There were 28 products with sales between RMB 10 million and RMB 100 million [1] - Ten products had sales between RMB 5 million and RMB 10 million [1] Key Product Highlights - Sales revenue for the Liu Wei Di Huang Wan series increased by approximately 47.99% year-on-year [1] - Sales revenue for the Jin Kui Shen Qi series grew by about 19.55% year-on-year [1] - Sales revenue for the Jing Zhi Niu Huang Jie Du Pian series rose by 4.03% year-on-year [1] - Sales for the Gan Mao Qing Re Granules and Sheng Mai Yin Oral Liquid series saw a decline compared to the previous year [1] - The "Big Variety Strategy" benefited products like Zhuang Yao Jian Shen Wan, Zhi Bai Di Huang Wan, and Gui Shao Di Huang Wan, which all achieved double-digit growth year-on-year [1]

Core Viewpoint - Tongrentang Technology (01666) reported a decrease in revenue and net profit for the six months ending June 30, 2025, primarily due to ongoing marketing reforms aimed at improving inventory turnover and market order [1] Financial Performance - The company achieved revenue of RMB 3.739 billion, a year-on-year decrease of 7.69% [1] - Net profit attributable to shareholders was RMB 339 million, down 21.01% year-on-year [1] - Basic earnings per share were RMB 0.26 [1] Product Sales Performance - The group had four products with sales exceeding RMB 100 million [1] - There were 28 products with sales between RMB 10 million and RMB 100 million, and 10 products with sales between RMB 5 million and RMB 10 million [1] - Key products showing significant growth included: - Six Flavor Rehmannia Pills series: sales increased by approximately 47.99% year-on-year [1] - Jinkui Shenqi Pills series: sales increased by approximately 19.55% year-on-year [1] - Jingzhi Niuhuang Jiedu Tablets series: sales increased by approximately 4.03% year-on-year [1] - Some products, such as Cold Relief Granules and Shengmai Drink, experienced a decline in sales [1] - Benefiting from the "big variety strategy," products like Zhuangyao Jian Shen Pills, Zhibai Dihuang Pills, and Guisha Dihuang Pills achieved double-digit growth year-on-year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代號：1666) 中期業績公告 截至二零二五年六月三十日止六個月 摘要 1 截至二零二五年六月三十日止六個月，本集團銷售收入較二零二四年同期下降約 7.69%。 截至二零二五年六月三十日止六個月，歸屬於本公司所有者之利潤較二零二四年同期 下降約 21.01%。 截至二零二五年六月三十日止六個月，歸屬於本公司所有者之每股收益為人民幣 0.26 元。 董事會決議不派發截至二零二五年六月三十日止六個月之中期股息。 中期業績(未經審核) 北京同仁堂科技發展股份有限公司（「本公司」或「公司」）之董事會 （「董事會」）欣然宣 佈本公司及其子公司（以下合稱「本集團」）截至二零二五年六月三十日止六個月（「報告 期」）未經審核之業績： 簡明合併利潤表(未經審核) | | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | --- ...

Core Insights - The event "Chinese Pharmacy · Beijing Tongrentang Technology Second Flavorful Xiaoyao Pill · Revitalizing Ancient Formula Pharmacy Speaker" was held in Beijing from August 20 to 22, focusing on the cultural heritage and contemporary value of traditional Chinese medicine [1] - The competition featured 60 pharmacy elites who showcased the charm of ancient formulas through professional presentations [1][6] Grouping 1 - The finalists were divided into "Tongrentang System" and "National Chain System" for multi-dimensional assessments, with industry experts providing professional feedback [6] - Participants utilized the history, culture, and philosophy of Tongrentang, along with their frontline sales experience, to share case studies on revitalizing ancient formulas [8] Grouping 2 - Contestants adhered to evidence-based medication principles, offering personalized medication suggestions based on patient conditions and explaining the evidence behind their recommendations [12] - Following the semi-final round, 30 finalists emerged from both groups, who will gather in September in Zhejiang Changxing for the next phase of the competition [12]

Core Viewpoint - The event organized by Beijing Tongrentang Technology Development Co., Ltd. focuses on addressing the health concerns of office workers through traditional Chinese medicine solutions, emphasizing the integration of health awareness into daily work life [1][7][13] Group 1: Health Issues and Solutions - Common health issues faced by office workers include acne from spicy food, fatigue from long hours, and emotional stress due to work pressure [2][5] - The company offers targeted products to address these specific health concerns, such as Jingzhi Niuhuang Jiedu Pian for heat relief, Huoxiang Zhengqi Shui for summer discomfort, and Ren Dan for boosting energy [5][9] Group 2: Event Engagement and Experience - The event featured interactive sessions where employees could learn about the products in relatable scenarios, enhancing their understanding and engagement [11][13] - The presence of experienced traditional Chinese medicine experts provided personalized consultations, addressing common issues like fatigue and stress-related insomnia [9][11] Group 3: Brand Trust and Community Building - The event aimed to build trust in the brand by allowing employees to experience the products firsthand, leading to positive word-of-mouth and potential repeat purchases [7][13] - The interactive and fun atmosphere of the event helped to foster a proactive approach to health among employees, making health knowledge more accessible and engaging [11][13] Group 4: Future Directions - The company plans to continue exploring ways to integrate traditional Chinese medicine into modern lifestyles, focusing on various workplace scenarios and health needs [13] - By leveraging technology and maintaining a caring approach, the company aims to keep traditional Chinese medicine relevant and beneficial for contemporary health challenges [13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 1 簡明合併損益表 | 未經審計 | 截至 | 6 | 月 | 30 | 日止六個月 | | --- | --- | --- | --- | --- | --- | | 2025年 | 2024年 | 千港元 | 千港元 | | | | 收入 | 664,518 | 761,736 | 銷售成本 | (212,748) | (298,698) | | 毛利 | 451,770 | 463,038 | 分銷及銷售開支 | (129,014) | (102,641) | | 一般及行政開支 | (74,685) | (88,659) | 金融資產之淨減值損失（計提）╱撥回 | 6,907 | (7,334) | | 淨其他利得 | 3,900 | 937 | 經營利潤 | | | | 258,878 | 265,341 | 財務收益 | 34,965 | 27,520 | | | 財務支出 | (3,219 ...

此外，董事会于2025年8月18日决议委任张春友先生为董事会的战略与规划委员会委员，并于同日生 效。 同仁堂（600085）科技(01666)发布公告，经股东于股东特别大会批准后，董事会仅此宣布，自2025年8 月18日起，张春友先生及温凯婷女士获委任为公司第九届董事会的执行董事。邸淑兵先生、陈加富先生 及冯智梅女士辞任非执行董事亦于同日起生效。 ...

此外，董事会于2025年8月18日决议委任张春友先生为董事会的战略与规划委员会委员，并于同日生 效。 智通财经APP讯，同仁堂科技(01666)发布公告，经股东于股东特别大会批准后，董事会仅此宣布，自 2025年8月18日起，张春友先生及温凯婷女士获委任为公司第九届董事会的执行董事。邸淑兵先生、陈 加富先生及冯智梅女士辞任非执行董事亦于同日起生效。 ...